Recombinant Rabbit Tissue factor (F3)

What is Tissue Factor (F3) and what are its primary functions in hemostasis?

Tissue Factor (F3), also known as CD142, Thromboplastin, or Coagulation factor III, is a transmembrane glycoprotein that serves as the primary initiator of the extrinsic blood coagulation pathway. It functions by binding to Factor VII/VIIa, forming a complex that activates Factors IX and X, ultimately leading to thrombin generation and fibrin formation.

In physiological conditions, F3 is constitutively expressed in subendothelial tissues and becomes exposed to blood following vascular injury. Recent research has demonstrated that F3 not only participates in hemostasis but also plays critical roles in inflammation, cellular signaling, and senescence pathways . The protein has emerged as a potential link between thrombotic events and inflammatory responses, particularly in conditions such as respiratory viral infections .

How is recombinant Rabbit Tissue Factor (F3) typically produced for research applications?

Recombinant Rabbit Tissue Factor is typically produced using bacterial expression systems, most commonly E. coli. The production process generally follows these steps:

• Cloning of the F3 gene sequence (commonly the extracellular domain, aa33-292) into an appropriate expression vector

• Transformation of E. coli cells with the expression construct

• Induction of protein expression using IPTG or other inducers

• Cell lysis and extraction of the recombinant protein

• Protein purification using affinity chromatography methods

Commercial preparations, such as those available from research suppliers, typically express the extracellular domain (aa33-292) of Rabbit F3 in E. coli systems . The recombinant protein generally lacks post-translational modifications present in native F3 but retains the ability to initiate coagulation in functional assays.

What are the differences between full-length and truncated recombinant F3?

The availability of different F3 constructs allows researchers to study specific functional domains:

The extracellular domain (aa33-292) is most commonly used in coagulation research as it contains the Factor VII binding site and maintains procoagulant activity while being soluble in aqueous solutions . This construct is typically supplied as a lyophilized powder that requires reconstitution before use in experimental applications.

What are the recommended protocols for using recombinant Rabbit Tissue Factor (F3) in coagulation assays?

When designing coagulation assays using recombinant Rabbit Tissue Factor (F3), researchers should consider the following methodology:

Protocol for prothrombin time (PT) assay:

• Reconstitute lyophilized recombinant F3 with sterile water to a final concentration of 1 mg/ml

• Prepare working dilutions in buffer containing calcium (typical dilution range: 1:1,000-5,000)

• Pre-warm reagents to 37°C

• Add 100 μL of plasma sample to test tube

• Add 200 μL of the diluted recombinant F3 reagent

• Start timer immediately upon addition

• Record time to clot formation

For TF activity assays:

• Prepare a standard curve using known concentrations of active TF

• Assay samples alongside standards

• For factor Xa generation assays, combine recombinant F3 with Factor VII, Factor X, and calcium

• Measure Factor Xa generation using chromogenic substrates

• Calculate activity based on standard curve

When validating experimental setup, Western blotting can be performed using anti-F3 antibodies with recommended work dilutions of 1:1,000-5,000 . ELISA applications typically employ more dilute antibody preparations, with recommended dilutions around 1:64,000 .

How should recombinant Rabbit Tissue Factor (F3) be stored and handled to maintain optimal activity?

Proper storage and handling of recombinant F3 is critical for maintaining its biological activity:

Reconstituted protein should be prepared fresh from the lyophilized form using sterile water to a final concentration of 1 mg/ml . For optimal storage stability, it is recommended to prepare small aliquots and store at -20°C to -70°C to avoid repeated freeze-thaw cycles that can compromise protein activity . Once thawed, reconstituted protein may be stored at 4°C for up to 2-4 weeks, but prolonged storage at this temperature is not recommended .

What controls should be included when using recombinant Rabbit Tissue Factor (F3) in experimental setups?

Rigorous experimental design requires appropriate controls to ensure valid interpretation of results:

Essential controls for F3 functional assays:

• Positive control: Commercial human TF preparation with known activity

• Negative control: Buffer-only sample

• Heat-inactivated F3 sample (56°C for 30 minutes)

• Factor VII-depleted plasma (for coagulation assays)

• Anti-TF antibody inhibition control

Additional controls for specific applications:

• For species cross-reactivity studies: Side-by-side testing with human and rabbit F3

• For concentration-dependency: Serial dilutions of active F3

• For signaling studies: Phosphatase inhibitor controls

When performing Western blot validation, include a recombinant protein F3 lane as a positive control. Commercially available recombinant F3 from E. coli typically appears at approximately 19kDa on Western blots .

How can genetic models be used to study Tissue Factor (F3) function?

The development of genetic models has significantly advanced our understanding of F3 biology:

Zebrafish model insights:
Zebrafish have two copies of the tissue factor gene (f3a and f3b) resulting from an ancestral teleost fish duplication event . This genetic duplication provides unique opportunities to study subfunctionalization of tissue factor:

Complete loss of both F3 genes in zebrafish (aa/bb genotype) is compatible with embryonic through juvenile development but leads to early adult lethality . Importantly, a single allele of either gene is sufficient to enable survival into adulthood, demonstrating functional redundancy between the paralogs.

CRISPR/Cas9 technology has been successfully employed to generate loss-of-function alleles in both copies of zebrafish f3, enabling detailed investigation of tissue factor function in hemostasis that would otherwise be challenging to study in mammalian systems where complete loss of F3 is embryonically lethal .

How does Tissue Factor (F3) function in the context of the coagulation cascade?

Tissue Factor initiates the extrinsic coagulation pathway through a series of molecular interactions:

• F3 binds to Factor VII, promoting its activation to Factor VIIa

• The F3/FVIIa complex activates Factor X to Factor Xa

• Factor Xa, as part of the prothrombinase complex, converts prothrombin to thrombin

• Thrombin cleaves fibrinogen to fibrin, forming the clot

Research in zebrafish models has revealed important insights about the differential roles of F3 in various vascular beds:

• In venous circulation: TF primarily mediates clot formation through canonical activation of FX by TF/FVII, with TFa showing higher efficiency than TFb

• In arterial circulation: TFb plays a critical role, with loss of TFb resulting in occlusion failure rates of 60-86% depending on genetic background

Intriguingly, the relationship between F3 and Factor IX varies between vascular beds. FIX significantly enhances TFb-mediated clot formation, with a larger effect observed in arterial circulation compared to venous systems .

What is the relationship between Tissue Factor (F3), inflammation, and cellular senescence?

Recent research has uncovered important connections between Tissue Factor, inflammatory processes, and cellular senescence:

Analysis of bronchoalveolar lavage fluid (BALF) from patients with respiratory viral infections has shown that upregulation of F3 occurs concurrently with the upregulation of senescence-associated secretory phenotype (SASP) factors . Furthermore, F3 levels positively correlate with both senescence and hyper-coagulation gene signatures in COVID-19 patients .

These findings suggest F3 functions as a critical link between:

• Inflammatory responses

• Thrombotic complications

• Cellular senescence processes

This emerging area of research has significant implications for understanding the pathophysiology of conditions characterized by both inflammation and thrombosis, such as severe COVID-19. The identification of F3 as a potential mechanistic link between these processes provides new avenues for therapeutic intervention targeting the intersection of inflammation and coagulation.

How can inconsistent results with recombinant Rabbit Tissue Factor (F3) be addressed?

When encountering variability in experimental outcomes with recombinant F3, consider these troubleshooting approaches:

For Western blotting applications specifically:

• Verify antibody dilution (recommended range 1:1,000-5,000)

• Confirm protein loading (19kDa for recombinant F3 from E. coli)

• Consider secondary antibody optimization (e.g., IRDye 800CW detection systems have been validated)

How should dose-response curves for recombinant Rabbit Tissue Factor (F3) be interpreted?

Proper interpretation of dose-response relationships for F3 requires understanding several key principles:

• Linear range determination:

  • Perform serial dilutions (typically 1:2 or 1:5) of recombinant F3

  • Plot activity vs. concentration on both linear and logarithmic scales

  • Identify the linear portion of the curve for quantitative applications

• Threshold effects:

  • F3 exhibits threshold effects in coagulation assays

  • Below critical concentration, minimal activity may be observed

  • Small increases above threshold can produce large changes in activity

• Plateau phenomena:

  • At high concentrations, response saturation occurs

  • Additional F3 produces minimal further activation

  • Important to work within dynamic range

Zebrafish model studies have demonstrated that F3 function exhibits distinct thresholds in different vascular beds. For example, in arterial injury models, TFb function shows a binary phenotype where vessels either occlude or fail to occlude, with the occlusion time remaining consistent across genotypes when occlusion does occur .

What factors contribute to differences between in vitro and in vivo activity of Tissue Factor (F3)?

Several factors explain the frequently observed discrepancies between in vitro and in vivo TF activity:

1. Microenvironmental factors:

• Phospholipid composition influences F3 activity

• Cell surface presentation affects accessibility to coagulation factors

• Local calcium concentration modulates reaction kinetics

2. Regulatory mechanisms:

• Tissue Factor Pathway Inhibitor (TFPI) regulates F3 activity in vivo

• Endothelial thrombomodulin/protein C system modulates downstream effects

• Fibrinolytic system influences clot stability

3. Experimental considerations:

• Recombinant proteins often lack post-translational modifications

• Buffer conditions may not recapitulate physiological complexity

• Static in vitro systems miss flow dynamics

Research in zebrafish has provided valuable insights into these differences. For example, studies demonstrated that TFa has higher procoagulant activity than TFb in vitro and is sufficient for venous hemostasis, while TFb is sufficient for arterial coagulation in vivo . These differences highlight the importance of considering physiological context when interpreting F3 activity data.

What emerging applications exist for recombinant Rabbit Tissue Factor (F3) in biomedical research?

Recombinant F3 is finding utility in several cutting-edge research areas:

• Tissue-specific thrombosis models:

  • Using F3 with tissue-specific targeting moieties

  • Developing localized thrombosis models with precise spatiotemporal control

  • Studying organ-specific thrombotic pathologies

• Drug development platforms:

  • High-throughput screening for modulators of the extrinsic coagulation pathway

  • Testing novel anticoagulants with improved specificity

  • Development of tissue factor-targeting therapeutics

• Biomarker development:

  • Standardization of F3 activity and antigen assays

  • Correlation of F3 levels with disease progression

  • Development of point-of-care diagnostics for coagulopathies

• Senescence and inflammation research:

  • Investigation of F3's role in cellular senescence pathways

  • Exploration of the F3-inflammation-senescence axis in age-related diseases

  • Development of interventions targeting F3 to modify SASP

Research in zebrafish models has demonstrated the value of studying F3 gene duplication and subfunctionalization, which could inform development of targeted therapies that selectively inhibit specific aspects of tissue factor function while preserving others .

How might understanding Tissue Factor (F3) genetic variants advance personalized medicine?

Genetic variation in F3 has significant implications for individualized approaches to thrombotic disorders:

Current knowledge gaps:

• Limited understanding of rare F3 variants

• Incomplete characterization of promoter polymorphisms affecting expression

• Need for systematic studies correlating variants with clinical outcomes

Research opportunities:

• Comprehensive sequencing of F3 in diverse populations

• Development of functional assays for variant characterization

• Integration of F3 genotyping into clinical risk assessment

The zebrafish model has demonstrated that even subtle changes in F3 function can have significant phenotypic consequences depending on the vascular bed and genetic background . Similar principles likely apply to human F3 variants, suggesting that detailed characterization of genetic variation could significantly enhance risk stratification and treatment selection in thrombotic disorders.